PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoE.
about
Atherogenesis and metabolic dysregulation in LDL receptor-knockout rats.PCSK9 and Atherosclerosis - Lipids and Beyond.Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9).Local effects of human PCSK9 on the atherosclerotic lesion.Novel method for reducing plasma cholesterol: a ligand replacement therapy.Anacetrapib reduces (V)LDL cholesterol by inhibition of CETP activity and reduction of plasma PCSK9.Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms.Episomal Nonviral Gene Therapy Vectors Slow Progression of Atherosclerosis in a Model of Familial Hypercholesterolemia.Comment on "Hypercholesterolemia with consumption of PFOA-laced Western diets is dependent on strain and sex of mice" by Rebholz S.L. et al. Toxicol. Rep. 2016 (3) 46-54.PCSK9 deficiency reduces atherosclerosis, apolipoprotein B secretion, and endothelial dysfunction.The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice.Non-Native Conformational Isomers of the Catalytic Domain of PCSK9 Induce an Immune Response, Reduce Lipids and Increase LDL Receptor Levels.Reduced Blood Lipid Levels With In Vivo CRISPR-Cas9 Base Editing of ANGPTL3.The BCR-ABL1 Inhibitors Imatinib and Ponatinib Decrease Plasma Cholesterol and Atherosclerosis, and Nilotinib and Ponatinib Activate Coagulation in a Translational Mouse Model.Proprotein convertase subtilisin-kexin type 9 as a biomarker for the severity of coronary artery disease
P2860
Q30968588-DAE39D29-D8ED-4FD2-9B5A-5EFC5F57BB2BQ33675963-3A26E70A-F075-4990-B87A-3450E69F962BQ34458693-EF7E9BD5-E856-4A91-80C8-2B0D9A1F54C3Q34492178-DC9ABAE3-AFD2-4225-AB10-C44902D987ADQ35558371-E86D7B0B-2955-4DA0-951C-6394A6E8B3EAQ36197815-5E02EC48-1E0D-434D-B1C4-40CB6B865793Q36812669-38D790BF-C1CA-4EFD-82E6-F69E930ECA20Q37501577-FCF6E91F-7CEC-4667-B33D-EE533AD97C4FQ41679609-2EC2A244-B4FE-416E-B0B0-914708B21C6BQ49459817-6A420A90-1EFD-49D3-A1D0-1914ACC2ED15Q50931633-41A156FC-5693-4AC2-A13C-F020C9F1EF31Q51766347-5952CF02-BF3D-42DD-987D-530FBFFA8AFFQ52430495-1CC1B6B9-0F9A-4F9C-B9E9-CF60E74EE5E7Q55401609-C46E4AF0-2DCB-4D55-8105-34C4F8CB874CQ58258510-E0DE7231-1EE1-4F3A-AAFE-BD1F7A6A6D07
P2860
PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoE.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
PCSK9 inhibition fails to alte ...... erosis in the absence of ApoE.
@ast
PCSK9 inhibition fails to alte ...... erosis in the absence of ApoE.
@en
type
label
PCSK9 inhibition fails to alte ...... erosis in the absence of ApoE.
@ast
PCSK9 inhibition fails to alte ...... erosis in the absence of ApoE.
@en
prefLabel
PCSK9 inhibition fails to alte ...... erosis in the absence of ApoE.
@ast
PCSK9 inhibition fails to alte ...... erosis in the absence of ApoE.
@en
P2093
P2860
P356
P1476
PCSK9 inhibition fails to alte ...... lerosis in the absence of ApoE
@en
P2093
Brandon Ason
Edward Lee
Elsbet J Pieterman
J Wouter Jukema
José W A van der Hoorn
Joyce Chan
Kathy Khanh Nguyen
Margrit Schwarz
P2860
P304
P356
10.1194/JLR.M053207
P577
2014-09-25T00:00:00Z